LivaNova surges on strong revenue beat, Medicare reimbursement boost
Medical device maker raises FY26 guidance as VNS Therapy payments jump 48%
LivaNova shares climbed to their highest level in a year on Wednesday after the medical device company reported stronger-than-expected fourth-quarter revenue and detailed significant reimbursement increases for its epilepsy treatment that will begin next month.
The London-based company, which specializes in therapeutic solutions for cardiovascular and neuromodulation diseases, reported adjusted earnings per share of $0.86 for the fourth quarter of 2025, beating analyst expectations of $0.80. Revenue reached $360.9 million, a 12.1% increase on a reported basis compared to the prior-year period and ahead of the $354.31 million consensus estimate.
For the full year 2025, LivaNova delivered revenue of $1.39 billion, up 10.7% year-over-year, with adjusted EPS of $3.90, representing a 15.4% increase compared to 2024.
But investors focused primarily on the company's outlook for 2026, when a substantial boost in Medicare reimbursement rates for its VNS Therapy—used to treat drug-resistant epilepsy—is set to take effect. The U.S. Centers for Medicare and Medicaid Services has assigned new patient implants to a New Technology Ambulatory Payment Classification, resulting in an expected 48% increase in hospital outpatient payments for these procedures starting January 1, 2026.
"These changes are anticipated to improve hospital economics for VNS Therapy, reduce barriers to procedure adoption, and expand patient access," the company stated in its earnings materials.
LivaNova issued full-year 2026 guidance calling for constant-currency revenue growth of 6% to 7% and adjusted EPS in the range of $4.15 to $4.25, with free cash flow expected to reach $160 million to $180 million. The company also received U.S. Food and Drug Administration approval for its cloud-based digital health platform, expanding its technological capabilities.
The stock, which has more than doubled from its 52-week low of $32.48, was trading at $69.05, just below its recent peak of $69.52. The company now commands a market capitalization of $3.7 billion.
Analysts remain broadly positive on the stock. Eleven analysts cover LivaNova, with nine rating it a buy or strong buy and just two recommending hold, according to market data. The consensus target price stands at $73.00, representing potential upside of nearly 6% from current levels.
The Medicare reimbursement increase represents a meaningful catalyst for LivaNova's neuromodulation business, which includes the VNS Therapy system. The therapy delivers mild electrical pulses to the vagus nerve and is used as an adjunctive therapy for reducing seizure frequency in adults with drug-resistant epilepsy.
The heightened payments come at a critical time for the company, which has been working to expand adoption of its neuromodulation technologies while maintaining growth in its cardiovascular business. The 48% increase for new patient implants, combined with a 47% boost for end-of-service procedures, should significantly improve the economics for hospitals considering the treatment.
LivaNova's strong fourth-quarter performance was driven by growth across both business segments, though the company did not break out specific divisional performance in its initial release. The forward price-to-earnings ratio stands at 12.6, suggesting the market is pricing in continued execution on the 2026 growth targets.
With the new Medicare reimbursement structure taking effect in just days, investors will be watching closely for early indications of adoption momentum in the first quarter and beyond. The company has scheduled its earnings conference call for Wednesday morning, where management is expected to provide more detailed commentary on the implementation timeline and potential market impact of the payment changes.